/ /

Vanessa Caceres
Fixed-combination glaucoma agent yields positive safety, efficacy data
A phase III trial for the fixed-combination netarsudil/latanoprost agent (Roclatan, Aerie Pharmaceuticals)reports positive results. The company plans to submit a NDA for the drug in early 2018.
Progression of visual field loss not always easy to test, analyze
Assessing visual field progression in glaucoma may be more of an art than a science—and there is no one test to give reliable information that is needed about a patient, said Chris A. Johnson, PhD, DSc, FAAO, FARVO, professor, Department of Ophthalmology, and director, Visual Field Reading Center, University of Iowa, Iowa City.
PiXL appears promising for low myopia
The use of epi-on photorefractive intrastromal cross linking reduced myopia by about 0.25 D in a small study; In a high-oxygen group, the effect averaged 1.25 D.
Visual acuity, other tasks appear unaffected by inlay decentration
Decentration of less than 0.75 mm from a light-constricted pupil with a novel corneal inlay for the surgical correction of presbyopia does not affect visual acuity, task performance, or severity of halos and glare.
OCT imaging yields better visualization
Future increases in imaging speed will improve performance and functionality for OCT and OCT angiography (OCTA), said James Fujimoto, PhD.
Phaco technology evolves over time
Fifty years after the idea for phacoemulsification came to Charles Kelman, MD, few would have predicted that surgical platforms would evolve to where they are today.
Phaco turns 50
Phaco turns 50
As the ophthalmic community celebrates 50 years of phacoemulsification (phaco) innovation, surgeons and industry alike mark its progress since the inspiration for the procedure came to Charles Kelman, MD, after a visit to the dentist.
New hypersonic vitrector introduces concept of ‘vitreous liquefaction’
New hypersonic vitrector introduces concept of ‘vitreous liquefaction’
A new hypersonic liquefaction vitrectomy system, called Vitesse PPVX (Bausch + Lomb), offers several advantages over currently available vitrector technology. The device received FDA 510k approval in April 2017.
Nystagmus diagnosis begins with thorough eye exam
A careful clinical workup, along with genetic testing, can help pinpoint what is behind congenital and infantile nystagmus.
Better diagnosis, treatment options key to nonresponsive bacterial keratitis
New treatment possibilities for nonresponsive bacterial keratitis are continually in development, including molecular-targeted therapy, the cautious use of topical corticosteroids, corneal crosslinking for superficial keratitis, and biologicals, Eduardo C. Alfonso, MD, reported.